Olema Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
All right. Let's get started here. Welcome everybody to the Wednesday afternoon of the 41st annual JPMorgan Healthcare Conference. My name is Anupam Rama, I'm one of the Senior Biotech Analyst here at JPMorgan. I'm joined by Malcolm Kuno and Priyanka Grover from the team. Our next presenting company is Olema. And presenting on behalf of the company, we have CEO, Sean Bohen.
Thanks very much, Anupam. Thank you, everybody, for joining us today. It's nice to be in person. This slide is when you all be familiar with forward-looking statements -- there are some in here.
So our objective at Olema oncology is to develop better therapeutic options for cancer, particularly cancers that are current primarily women. So our lead drug and only clinical candidate is OP-1250. It's targets -- the validated target, the estrogen receptor in ER+ breast cancer.
And we have several attributes of OP-1250 that we are looking for to be best in class to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
